Danshao Huaxian capsule in treatment of decompensated cirrhosis resulting from chronic hepatitis B

Hepatobiliary and Pancreatic Diseases International

Volumn 5, Issue 1, 2006, Pages 48-51

  Cheng, Ming Liang ^a   Lu, Tong ^b   Yao, Yu Mei ^a   Geng, Xiao Xia ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Chronic hepatitis B; Danshao Huaxian capsule; Decompesated cirrhosis; Prognosis

Indexed keywords

ALBUMIN; ASPARTIC ACID; ASTRAGALUS EXTRACT; BILIRUBIN; CHINESE DRUG; DANSHAO HUAXIAN; GINKGO BILOBA EXTRACT; METHIONINE; PAEONIA RADIX; PLANT EXTRACT; SALVIA MILTIORRHIZA EXTRACT; STEPHANIA TETRANDRA EXTRACT; TYROSINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ALBUMIN BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; STATISTICAL SIGNIFICANCE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

CAPSULES; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33644540761     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cheng ML, Yang CQ. The basic study and clinical research on hepatic fibrosis. 2nd ed. Beijing: People's Health Publishing House; 2002:1-20.
2. Cheng ML, Wu YY, Huang KF. Clinical study on the treatment of liver fibrosis due to hepatitis B by IFN-2, and traditional medicine preparation. World J Gastroenterol 1999; 5: 267-269.
3. Li CX, Huang LH, Cheng ML. The protective effects of traditional Chinese medicine prescription, Han-Dan-Gan-Le, on CCl4 induced liver fibrosis in rats. Am Tradit J Chin Med 1998;28:325-332.
4. Cheng ML, Lu T, Wu YY. Effect of Han-Dan-Le and interferon on the early stage of cirrhosis. Chin J Trad-Western 1995;15:300-303.
5. Cheng ML, Lu YY, Wu J. Clinical study on treatment hepatic fibrosis with Handan Ganle copswe. CJIM 2001;7:16-18.
6. Knodel KG, Ishak KG. Formulation and application of a numezcal scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-434.
7. Chwvallire M, Guerret S. A histological semi-quantitative scoring system for evaluation of hepatic fibrosis in needle liver. Biopsy specimens-comparison with morphormetive studies. Hepatology 1992;22:349-355.
8. Lu YY, Lu T, Cheng ML. Changes of collagenase activity in immune hepatic fibrosis following pig's serum injection and therapeutic effect of HanDanGanle. Chin J Hepatol 2000; 2: 108-109.
9. Desment VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
10. Coflishing on Infectious Disease and Parasitic Disease of Chinese Medical Association. Prevention and treatment program on viral hepatitis (provisional). Chin J Infec Dis 1995; 13: 241-247.
11. Cheng ML, Liu SD. The basic study and clinical practice on hepatic fibrosis. 1st ed. Beijing: People's Health Publishing House; 1996:228-258.
12. Li W, Dai QT, Liu ZE. The primary observation on early hepatic fibrosis of chronic hepatitis B treated by Gingko biloba granule. CJIM 1995;15:593-595.
13. Ruwart MJ, Rush BD, Snyder KF, Peters KM, Appelman HD, Henley KS. 16, 16-Dimethyl prostaglandin E2 delays collagen formation in nutritional injury in rat liver. Hepatology 1988;8:61.
14. Shah H. Formation of carbonyl choride in carbon tettraholride metabolism by rat liver in vitro. Cancer 1997;39:3942.
15. Kasaragod AB, Lucia MS, Cabirac G, Grotendorst GR, Stenmark KR. Connective tissue growth fac or expression in pediatric myofibroblastic tumors. Pediatr Dev Pathol 2001; 437-445.
16. Periuo DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis Be antigen V positive chronic hepatitis B. Ann Intern Med 1993;119:312-323.
17. Williams EJ, Gaca NM, Brigstock DR, Arthur MJ, Benyon RC. Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 2000;32:754-761.
18. Benyon BC, Arthur MJ. Mechanisms of hepatic fibrosis. J Pediatr Gastroenterol Nutr 1998;27:75-85.
19. Grotendorst GR. Connective tissue growth factor: a mediator of TGF beta action on fibriblasts. Cytokine Growth Factor Rev 1997;8:171-179.
20. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cella and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000;11:25-38.
21. Zhang FK. Interferon-alfa in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004;3:337-340.
22. Sun Y, Chen HY, Xin SJ. Effect of IL-18 on peripheral blood mononuclear cells of chronic hepatitis B and hepatitis B virus DNA released by HepG2. 2. 15 cell lines Hepatobiliary Pancreat Dis Int 2004;3:230-234.
23. Long Y, Lin XT, Zeng KL, Zhang L. Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2004;3:69-72.
24. Ruan P, Gong ZJ, Zhang QR. Changes of plasma D(-)-lactate, diamine oxidase and endotoxin in patients with liver cirrhosis. Hepatobiliary Pancreat Dis Int 2004;3:58-61.
25. Chen NL, Bai L, Deng T, Zhang C, Kong QY, Chen H. Expression of hepatitis B virus antigen and Helicobacter pylori infection in gastric mucosa of patients with chronic liver disease. Hepatobiliary Pancreat Dis Int 2004;3:223-225.